Most Read Articles
Roshini Claire Anthony, 12 Jun 2019

Women with platinum-sensitive ovarian cancer with germline BRCA mutations who relapsed after previously receiving 2 lines of chemotherapy demonstrated better objective response rates (ORRs) and progression-free survival (PFS) following treatment with olaparib than platinum-based chemotherapy, according to results of the SOLO3* trial.

Postmenopausal breast cancer survivors at heightened risk of CVD

09 Jul 2019

Postmenopausal breast cancer survivors are more likely to have risk factors for cardiovascular disease (CVD) compared with their counterparts who do not have the breast disease, a study has found.

Researchers examined 96 postmenopausal breast cancer survivors and 192 postmenopausal women, matched according to age, time since menopause and body mass index. Both groups included women with amenorrhea >12 months, aged ≥45 years and without established CVD.

Compared with no-cancer controls, breast cancer survivors had higher HSP60 levels and lower HSP70 levels (p<0.05). Furthermore, women treated for cancer had higher odds of developing metabolic syndrome (odds ratio [OR], 4.21, 95 percent CI, 2.28–7.76), atheromatous plaque (OR, 2.61, 1.19–5.72), diabetes (OR, 4.42, 1.86–10.49), hypertriglyceridemia (OR, 2.32, 1.33–4.0) and increased waist circumference (OR, 11.22, 4.0–31.65).

Metabolic syndrome was defined as the presence of three or more of the following criteria: waist circumference >88 cm, triglycerides ≥150 mg/dL, high-density lipoprotein cholesterol <50 mg/dL, blood pressure ≥130/85 mm Hg, and glucose ≥100 mg/dL.

Immunoassays (enzyme-linked immunosorbent assay test) facilitated measurement of plasma heat shock proteins (HSP) 60 and 70 concentrations, while atherosclerotic disease was determined by intima-media thickness (>1 mm) of the carotid arteries and/or the presence of atheromatous plaque assessed by carotid artery ultrasound (scanner duplex).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 12 Jun 2019

Women with platinum-sensitive ovarian cancer with germline BRCA mutations who relapsed after previously receiving 2 lines of chemotherapy demonstrated better objective response rates (ORRs) and progression-free survival (PFS) following treatment with olaparib than platinum-based chemotherapy, according to results of the SOLO3* trial.